Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8900216 | 1.00 | BRD4 (0.38) | BRD4CREBBPMAP3K14CYP1A2CYP2A6 | |
| SCHEMBL17818432 | 0.77 | CHRNB4 (0.41) | CA1CA2ALDH1A1ACHE | |
| SCHEMBL12856198 | 0.77 | MAP3K14 (0.34) | BRD4CREBBPMAP3K14CYP1A2CYP2A6 | |
| SCHEMBL25121292 | 0.77 | P2RY6 (0.30) | — | |
| SCHEMBL4498507 | 0.77 | CHRNB4 (0.41) | ALDH1A1TSHR | |
| SCHEMBL12422694 | 0.76 | BRD4 (0.32) | BRD4CREBBPCYP1A2 | |
| Hydrochloric Acid SCHEMBL31010881 | 0.75 | CHRNB4 (0.40) | ALDH1A1TSHR | |
| SCHEMBL20406703 | 0.75 | MAP3K14 (0.37) | BRD4CREBBPMAP3K14 | |
| SCHEMBL14428351 | 0.74 | MAP3K14 (0.33) | BRD4CREBBPMAP3K14CYP1A2CYP2A6 | |
| SCHEMBL13265245 | 0.74 | HTT (0.40) | BRD4CREBBPMAP3K14TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447677-B | The preparation method of 4-hydroxyl-2,2-dimethyl-1,3-benzodioxole | 湖南海利常德农药化工有限公司 | 2016-07-06 | — | — | CN | claimed |
| US-4808582-A | LEARNING ENHANCEMENT | DELALANDE S.A. (FR) | 1989-02-28 | — | — | US | claimed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2023164050-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023135564-A1 | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023076237-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022135572-A1 | FIVE-MEMBERED RING DERIVATIVE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-107922843-B | Material composition | 默克专利股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-107004768-B | Organic semiconductor composition containing a liquid medium | 巴斯夫欧洲公司 | 2020-08-21 | — | — | CN | disclosed |
| CN-109516923-A | Compounds and organic luminescent device comprising it | 东进世美肯株式会社 | 2019-03-26 | — | — | CN | disclosed |
| US-8513286-B2 | Iminipyridine derivatives and their uses as microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2012146125-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| WO-2008101682-A2 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046088-A1 | IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES | CD14, MYADM, MPO | BRD4 2298/4885CREBBP 4389/4885MAP3K14 3198/4885 |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR10 | BRD4 282/4885CREBBP 236/4885MAP3K14 3331/4885 |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | BRD4 482/4885CREBBP 1677/4885MAP3K14 2872/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | BRD4 1687/4885CREBBP 4189/4885MAP3K14 4782/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | BRD4 482/4885CREBBP 1677/4885MAP3K14 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.